Cytokinetics (CYTK) to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with HCM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street mixed as oil prices surge, investors await earnings, economic data
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 62.98 +0.07 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.91 | 52 Week High | $13.18 | |||
| Open | $62.48 | 52 Week Low | $6.00 | |||
| Day High | $63.50 | P/E | N/A | |||
| Day Low | $62.13 | EPS | $-1.24 | |||
| Volume | 736,383 | |||||
